• Exclusive manufacturing agreement with Stedical Scientific to produce PermeaDerm at AVITA's facility
• Amended distribution agreement with Stedical Scientific, adjusting revenue-sharing terms
• Agreements strengthen strategic relationship and expand reach of PermeaDerm

AVITA Medical, Inc. has announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm Biosynthetic Wound Matrix, along with an Amendment to its existing Exclusive Distribution Agreement with Stedical Scientific, Inc. These agreements further strengthen the strategic relationship between the two companies to expand the reach and availability of PermeaDerm. Under the new Contract Manufacturing Agreement, effective March 17, 2025, AVITA Medical will manufacture PermeaDerm at its state-of-the-art facility in Ventura, California. This ensures continued availability of the innovative transparent biosynthetic wound matrix while optimizing AVITA's production capabilities to meet growing market demand. The Exclusive Distribution Agreement originally executed in January 2024 has also been amended to align with the new manufacturing arrangement. The revised agreement modifies revenue-sharing terms, establishes performance-based milestones, and extends the contract term. Under the new terms, AVITA Medical will retain 60% of the average sales price from PermeaDerm sales, while remitting 40% to Stedical after deducting manufacturing costs. Prior to the amendment, each party retained 50% of the average sales price.

AVITA Medical expects the new manufacturing and distribution agreements to drive greater value through streamlined production, increased scale, and optimized manufacturing cost efficiencies. The agreements will ensure a robust supply chain and strengthen the companies' commitment to delivering cutting-edge solutions to the global market.